"Antithrombin III" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
| Descriptor ID |
D000990
|
| MeSH Number(s) |
D12.644.861.060.500 D12.776.124.790.106.125 D12.776.377.715.085.125 D12.776.872.060.500 D23.113.025
|
| Concept/Terms |
Antithrombin III- Antithrombin III
- Heparin Co-Factor I
- Heparin Co Factor I
- Serpin C1
- Heparin Cofactor I
- Cofactor I, Heparin
|
Below are MeSH descriptors whose meaning is more general than "Antithrombin III".
Below are MeSH descriptors whose meaning is more specific than "Antithrombin III".
This graph shows the total number of publications written about "Antithrombin III" by people in this website by year, and whether "Antithrombin III" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 2 | 0 | 2 |
| 1997 | 2 | 1 | 3 |
| 1998 | 1 | 4 | 5 |
| 1999 | 3 | 0 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 5 | 5 |
| 2002 | 0 | 4 | 4 |
| 2003 | 1 | 2 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 3 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 4 | 4 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
Below are the most recent publications written about "Antithrombin III" by people in Profiles.
-
Antithrombin, Protein C, and Protein S: Genome and Transcriptome-Wide Association Studies Identify 7 Novel Loci Regulating Plasma Levels. Arterioscler Thromb Vasc Biol. 2023 07; 43(7):e254-e269.
-
Antithrombin Therapy: Current State and Future Outlook. Clin Appl Thromb Hemost. 2023 Jan-Dec; 29:10760296231205279.
-
Management of Myocardial Infarction in Children with Giant Coronary Artery Aneurysms after Kawasaki Disease. J Pediatr. 2020 06; 221:230-234.
-
Glial cells maintain synapses by inhibiting an activity-dependent retrograde protease signal. PLoS Genet. 2019 03; 15(3):e1007948.
-
Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Effects of Antithrombin Versus Placebo on the Coagulation System in Infants with Low Antithrombin Undergoing Congenital Cardiac Surgery. J Cardiothorac Vasc Anesth. 2019 02; 33(2):396-402.
-
Thromboelastographic characterization of the activated clotting system in children with sickle cell trait or sickle cell disease. Thromb Res. 2017 Mar; 151:44-50.
-
Brain regulation of thrombosis and hemostasis: from theory to practice. Stroke. 2013 Nov; 44(11):3275-85.
-
Antithrombin III administration in neonates with congenital diaphragmatic hernia during the first three days of extracorporeal membrane oxygenation. J Pediatr Surg. 2013 Sep; 48(9):1837-42.
-
A principal component analysis of coagulation after trauma. J Trauma Acute Care Surg. 2013 May; 74(5):1223-9; discussion 1229-30.
-
Secreted phosphoprotein-24 kDa (Spp24) attenuates BMP-2-stimulated Smad 1/5 phosphorylation and alkaline phosphatase induction and was purified in a protective complex with alpha2 -Macroglobulins From Serum. J Cell Biochem. 2013 Feb; 114(2):378-87.